Vitalex Bioscience
@VitalexBioscien
Followers
14
Following
45
Media
1
Statuses
49
Vitalex Biosciences, LLC is a stealth biotech startup currently focused on immunotherapy and diagnostics. for contact: [email protected]
Torrance, CA, USA
Joined May 2021
The Lundquist Institute, together with its start-up company @VitalexBioscien, is proud to announce a significant advancement in fungal vaccine research.🔬 Supported by a highly competitive $40 million contract from the NIH’s @NIAIDNews, the team is moving its second-generation,
1
4
7
What an incredible way to kick off 2025! We had a great time yesterday at our Town Hall Meeting where we were able to hear our new President and CEO Dr. @joewramos' vision for TLI. We're excited and grateful for Dr. Ramos' #leadership and can't wait for him to share his vision
0
3
6
In part 2 with Dr. Ashraf Ibrahim, he discussed the 20-year-long journey behind VX-01, a humanized monoclonal antibody designed to block mucormycosis angioinvasion. Listen here: https://t.co/uBfTSu4YpT
0
1
1
Researchers have developed VX-01, a monoclonal antibody that blocks fungal invasion of blood vessels in mucormycosis. Part 1 of our interview w/ Dr. Ashraf Ibrahim explains how this approach enhances immune response in high-risk patients. Listen: https://t.co/ZvVYV3SamR
1
1
2
Honored to welcome @SenBillCassidy to @the_lundquist. I showed him @IbrahimLab3, where we study host–pathogen interactions, develop immunotherapies for mucormycosis, and advance vaccines against drug-resistant infections. Grateful for his support of biomedical research.
1
4
15
IT'S A TWO-FER! A huge congratulations to TLI Investigator @IbrahimLab3 for receiving the 43rd Kuwait Prize by the @KuwaitFAS. This prestigious award honors Kuwaiti and Arab scientists for their exceptional scientific and intellectual contributions on a global scale.🚀 Dr.
0
2
4
Mucormycosis is a fungal infection that causes severe disease and fatality. “Mucormycosis usually occurs in patients who suffer from weakened immune system, such as patients with poorly controlled diabetes, cancer patients undergoing chemotherapy, and transplant patients,” says
0
5
8
Humanizing Monoclonal Antibodies for Mucormycosis Treatment https://t.co/NaPbRtLJ6K via @contagionlive @the_lundquist @VitalexBioscien
contagionlive.com
Ashraf S. Ibrahim, PhD, details over 20 years of research on a spore-coating protein and the development of VX-01 to block fungal tissue invasion.
1
1
3
Mucormycosis is a fungal infection that causes severe disease and fatality, especially in immunocompromised individuals. While vaccines and immunotherapeutics have been available in combating viral and bacterial infections, approved antifungal immunotherapies are lacking. Thanks
Scientists show that a humanized antibody that targets CotH fungal spore coat proteins can treat #mucormycosis in mice by augmenting host immunity, supporting its translation as one of the first antifungal #immunotherapies. @IbrahimLab3 @the_lundquist
https://t.co/Wr1Oq90Qel
0
2
2
Very Happy to see our humanized mAb VX-01 making it a step closer to clinical testing
0
0
0
A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response | Science Translational Medicine
science.org
An anti-CotH humanized IgG1 antibody protects against lethal mucormycosis when given as adjunctive therapy to immunocompromised mice.
0
0
0
@the_lundquist Investigator Ashraf Ibrahim, PhD, has been selected by the Medical Mycology Society of the Americas (MMSA) to receive the 2024 Billy H. Cooper Award for his continuous outstanding achievement in clinical mycology. TLI congratulates Dr Ibrahim for this high honor.
2
4
19
IND-enabling GLP toxicology study.  #NIAID/NIH #Vitalex #VX01 #mucormycosis #BrevisRefero Corporation #JOIN Biologics #treatment #fungalinfection #fungai #mold #lung #chemo #immunocompromised @IbrahimLab3
0
0
1
as well as JOINN Biologics for the process/analytical development and manufacturing of VX-01, and with the help of NIAID/NIH’s crucial SBIR Phase 2 grant award, Vitalex is now turning its attention to the scale-up and manufacturing of VX-01 to allow the completion of its
1
0
0
mucormycosis significantly on the rise including among COVID-19 patients, Vitalex’s VX-01 is a first-in-class mAb therapy targeted to prevent and control of infection and dissemination. Partnering with BrevisRefero Corporation for CMC program management and technical oversight,
1
0
0
NIAID/NIH. Despite debilitating surgical disfigurement and adjunctive fungal therapy, the overall mortality rate from mucormycosis is 50% and approaches 100% in patients with disseminated disease, persistent neutropenia, or brain infection. With the global prevalence of
1
0
0
Vitalex Biosciences, a spinoff start-up company of The Lundquist Institute for Biomedical Innovation, is proud to announce today that its VX-01 monoclonal antibody (mAb) program targeting the debilitating indication of mucormycosis has been awarded an SBIR Phase 2 grant from
1
0
1
The two contracts will amount to ~ $4M in funding to get VX01 closer to phase I clinical trials. #research #funding #testing #clinicaltrials #manufacturing #vitalex #nih #NIAID #fda #fungi #mucormycosis #therapies #blackfungus
1
1
2
If the Phase II SBIR grant is funded, Vitalex will be able to conduct manufacturing, test VX01 in tissue cross-reactivity studies and conduct IND-enabling GLP-toxicity studies.
2
1
1
The award was issued by NIAID Preclinical service (PCS) to select a Research Cell Bank to further the establishment of a Master Cell Bank. Vitalex also recently received a competitive score of 24 on a Phase II SBIR grant.
1
1
1